The Elivaldogene Autotemcel (Skysona®) Post-Infusion Supplemental Data Collection (2547) Form must be completed for recipients who are enrolled onto CIBMTR study CS20-51. This is a post-marketing prospective, multicenter, observational, long-term safety and effectiveness registry study of recipients with cerebral adrenoleukodystrophy treated with Elivaldogene Autotemcel (Skysona®).

The Pre-Transplant Essential Data (2400) Form will confirm study eligibility, this includes event date and gene therapy product infused. Once eligibility is confirmed, the Elivaldogene Autotemcel (Skysona®) Post-Infusion Supplemental Data Collection (2547) Form will come due with the Post-Infusion Data (2100) and Leukodystrophies Post-Infusion Data (2137) Forms for each follow up timepoint 100 day through 15 years annually, per FDA Gene Therapy Long Term Follow Up Guidelines.

Links to Sections of Form:
Q1-10 Growth Factor and Cytokine Therapy
Q11-14 Clinical Status Post-Infusion

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, you can reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
9/27/2024 Elivaldogene Autotemcel (Skysona®) Post-Infusion Supplemental Data Add Version 1 of the Elivaldogene Autotemcel (Skysona®) Post-Infusion Supplemental Data section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2547.
Last modified: Sep 30, 2024

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.